Endocrine therapy and urogenital outcomes among women with a breast cancer diagnosis
- 28 September 2016
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 27 (11) , 1325-1332
Abstract
Purpose Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers. Methods Urogenital and sexual symptoms were self-reported during the enrollment interview within the University of North Carolina Cancer Survivorship Cohort. Tumor characteristics and endocrine therapy use were collected from medical and prescription records. We calculated multivariable prevalence ratios (PR) and 95 % confidence intervals (CI) for the association of endocrine therapy (versus no endocrine therapy) and urinary incontinence, overall and by therapy type (tamoxifen or aromatase inhibitors). PROMIS Sexual Function and Satisfaction domain scores were compared across endocrine therapy groups. Results Among the 548 women with a breast cancer diagnosis, 49 % received endocrine therapy. Overall, 18 % of women reported urinary incontinence symptoms. We observed no association between urinary incontinence and endocrine therapy use overall (PR = 0.97; 95 % CI 0.67, 1.43), tamoxifen (PR = 1.20; 95 % CI 0.74, 1.96), or aromatase inhibitors (PR = 0.89; 95 % CI 0.55, 1.42), compared to no use. Approximately 55 % of women were sexually active. Sexual function scores did not vary according to endocrine therapy use, although urinary incontinence was associated with lower satisfaction scores (p = 0.05). Conclusions Our findings demonstrate a high prevalence of urinary incontinence after breast cancer diagnosis similar to the overall prevalence in older U.S. women, and this did not vary strongly according to use of endocrine therapy.Keywords
Funding Information
- National Center for Advancing Translational Sciences (KL2-TR001109)
This publication has 18 references indexed in Scilit:
- The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective studyBreast Cancer Research and Treatment, 2013
- Urinary incontinence and health-related quality of life among older Americans with and without cancer: a cross-sectional studyBMC Cancer, 2013
- Development of the NIH PROMIS® Sexual Function and Satisfaction Measures in Patients with CancerThe Journal of Sexual Medicine, 2013
- Oestrogen therapy for urinary incontinence in post-menopausal womenCochrane Database of Systematic Reviews, 2012
- Expression of estrogen receptors in the pelvic floor of pre- and post-menopausal women presenting pelvic organ prolapseFolia Histochemica et Cytobiologica, 2011
- Urogenital disorders in women with adjuvant endocrine therapy after early breast cancerAmerican Journal of Obstetrics and Gynecology, 2011
- Prevalence of Symptomatic Pelvic Floor Disorders in US WomenJAMA, 2008
- The long-term effect of raloxifene on the genitourinary tractClimacteric, 2007
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trialThe Lancet Oncology, 2006
- Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patientsAnti-Cancer Drugs, 2004